The content on this site is intended for healthcare professionals only
| Major findings of the KCCURE survey | ||
| Patients’ views on efficacy, toxicity and quality of life | ||
| The relevance of the questions addressed in the FKSI-19 and EORTC QLQ-C30 scores |
EMEA-ONC-26-00046 / March 2026
The impact of disease burden: Understanding patient priorities in aRCC
Understanding patient expectations and clinicians' goals in favourable risk aRCC patients
Combination therapeutic strategies for aRCC patients with bone metastases
Non-clear cell renal cell carcinoma: Management of papillary RCC
Treatment management of favourable risk and very favourable risk patients
Managing cardiotoxicities for RCC treatment – Cardiologist’s perspective
Managing gastrotoxicities for RCC treatment – Gastroenterologist's perspective
Durable responses in aRCC, how do we optimise treatment?
Patient expectations and shared decision making in aRCC
Do patients and doctors treatment aspirations align? KCCure survey – part A
